

Elisa Mantovani, MSc, PhD

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona

P.le L.A. Scuro 10, 37134 Verona, Italy

Date of Birth: [REDACTED]

E-mail: [REDACTED]

Contact (mobile phone): [REDACTED]

ORCID ID: [REDACTED]

SCOPUS AUTHOR ID: [REDACTED]

POSITION TITLE

Post-Doctoral Research Fellow, Neurology Unit - Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy; Psychologist with expertise in Clinical Neurosciences (Register of the Psychologists of the Region Lombardia, No: 21961).

AREAS OF RESEARCH AND CLINICAL INTERESTS

My main areas of research and clinical interest are related to cognitive and clinical neuropsychology (cognitive and neuropsychiatric alterations, in particular) in the context of neurological and neurodegenerative disorders (e.g., Parkinson's disease and other movement disorders, Alzheimer's disease and other dementias, multiple sclerosis and other neuroimmune disorders), substance use disorders and impulse control disorders (e.g., pathological gambling), infectious diseases (e.g., HIV, SARS-CoV-2 infection), and neurological complications (both central and peripheral) of cancer treatments. The main research tools are psychometric techniques (e.g., neuropsychological and psychological tests), computerized psychological testing tools (e.g., E-Prime), neurophysiological techniques (e.g., EEG, evoked potentials, non-invasive brain stimulation techniques), systematic reviews (e.g., Rayyan, Covidence), and meta-analyses (e.g., RevMan).

EDUCATION AND TRAINING

- **Jan. 2023 – Ongoing:** Residency in Cognitive Psychotherapy, School of Cognitive Psychotherapy – SPC, Verona, Italy (Degree: PsyD)
- **2019 – 2022 (defense: 24/03/2023):** PhD program in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences (Cycle XXXV), University of Verona, Italy (Degree: PhD)
- **Aug. 2019:** Licensed Psychologist, University of Padova, Italy
- **2018-2019:** II - Level University Master's Degree in Clinical Neurosciences: evaluation, diagnosis and neuropsychological and neuromotor rehabilitation, Catholic University of the Sacred Heart, Brescia, Italy
- **2015-2017:** MSc in Neuroscience and Neuropsychological Rehabilitation, University of Padova, Italy (Degree: MSc; Final grade: 108/110)
- **2012-2015:** BSc in Cognitive Psychology and Psychobiology, University of Padova, Italy (Degree: BSc; Final grade: 108/110)

OTHER COURSES ATTENDED

- **08/07/2020 – 28/07/2020** (total amount 20 h, PhD course in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences, University of Verona, Italy): *"MATLAB programming with applications to signal processing"*
- **06/05/2021 – 25/05/2021** (total amount 9 h, PhD course in Neuroscience, Psychological and Psychiatric Sciences, and Movement Sciences, University of Verona, Italy): *"Meta-analyses"*
- **01/04/2022 – 31/07/2022** (total CFU 26, Advanced course, School of Medicine, University of Verona, Italy): *"Systematic reviews and meta-analyses for the production of evidence-based guidelines in medical area"*

WORK EXPERIENCES

Main scientific experiences

- **Jul. 2023 – ongoing:** Research fellow (Program: *Translational aspects of intrathecal inflammation in multiple sclerosis: from bench to bedside - focus on neurodegeneration and cognitive deficits from a transdiagnostic perspective*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Jan. 2023 – Jun. 2023:** Research fellow (Program: *COVID-19, cognitive deficits and impulse control disorders in patients with Parkinson's disease*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Sept. 2021 – Dec. 2022:** Research fellow (Program: *Clinical and neurophysiological correlates of Impulse Control Disorders in Parkinson's disease*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Sept. 2020 – Aug. 2021:** Research fellow (Program: *Regional Project: Prevention and treatment of Pathological Gambling in Parkinson's disease*), Addiction Medicine Unit, Verona University Hospital, Italy
- **Jan. 2020 – Aug. 2020:** Research fellow (Program: *Anatomical correlates of Mild Cognitive Impairment in Parkinson's disease patients*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Oct. 2019 – Sept. 2022 (PhD defense: 24/03/2023):** PhD fellow (Program: *Neuropsychological, chemosensory, neuroimaging and neurophysiological markers of cognitive decline in Parkinson's disease*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Jan. 2019 – Jan. 2020:** Research fellow (Program: *Effectiveness of natural environment treatment for Sundowning Syndrome in Alzheimer's disease*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
- **Jan. 2018 – Jan. 2019:** Post-graduate Internship, Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy

Other scientific experiences

- **May 2021 – ongoing:** Research collaborator (Program: *Clinical predictors of treatment outcomes in Pathological Gambling*), Addiction Service, Mantova Local Health Unit, Italy
- **Jan. 2021 – ongoing:** Research Collaborator (Brain Research Foundation Verona 2021: *Tele-monitoring, physical therapy and nutrition in neurology - Parkinson's disease, chemotherapy-induced neurotoxicity, emotional eating disorders*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy (Anatomy and Histology, Neurology Sections; Dept. of Computer Science)
- **May 2020 – ongoing:** Research collaborator (Program: *Long-term effects of SARS-CoV-2 infection: analysis of olfactory-gustatory perceptual status and central neurological sequelae – COVIDOLFANEURO*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy (Anatomy and Histology, Neurology Sections)
- **Sept. 2019 – ongoing:** Research collaborator (Program: *HIV-Associated Neurocognitive Disorders: a clinical, virological and immunological approach to early definition of biomarkers*), Dept. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy (Biology and Genetics, Neurology Sections)

Ongoing clinical trials

- **Jan. 2023 – ongoing:** Research Assistant (Clinical trial: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease, SELECT-HD; ClinicalTrials.gov Identifier: NCT05032196)
- **Jan. 2023 – ongoing:** Research Assistant (Clinical trial: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group – ODYSSEY; EudraCT number: 2019-004730-42)

Clinical experiences

- **Apr. 2023 – ongoing:** psychological assessment and support activity as a resident in cognitive behavioral psychotherapy (Prof. Del Piccolo, Prof. Perlini), Clinical Psychology Unit, Verona University Hospital, Italy
- **Jun. 2022 - ongoing:** neuropsychological activity c/o "Cognitive dysfunction in Movement Disorders" outpatient clinic (Prof. Tinazzi), Parkinson's Disease and Movement Disorders Unit, Verona University Hospital, Italy
- **Jan. 2021 - ongoing:** neuropsychological activity c/o "Neuroimmunology" outpatient clinic (Dr. Ferrari, Dr. Mariotto), Neurology Unit, Verona University Hospital, Italy

TEACHING ACTIVITY

- **AA 2019/2020, 2020/2021, 2021/2022, 2022/2023, 2023/2024:** co-teaching lectures: "*Planning and execution of a systematic review - PRISMA guidelines; PROSPERO protocol registration; how to properly conduct a literature search; Rayyan, a systematic review web-based app*" c/o MSc Rehabilitation Science in Healthcare Professions, University of Verona, Italy
- **AA 2020/2021, 2021/2022, 2023/2024:** lectures: "*Research methodology: systematic reviews and meta-analyses; EEGLAB: practice; Neuropsychological sequelae of SARS-CoV-2 infection; Clinical cases*" c/o II - Level University Master's Degree Clinical and Experimental Neuropsychology, University of Verona, Italy

NATIONAL AND INTERNATIONAL COLLABORATIONS

- **DEMON Network** (<https://demon.dementia.com>) – **Frailty Special Interest Group** (Chair: David Ward); **Social Determinants of Dementia Special Interest Group** (Chair: Anouk F.J. Geraets); **Brain Epigenomics Special Interest Group** (Chair: Conceição Bettencourt)
- **IoT4Care** (Chair: Graziano Pravadelli; <https://www.di.univr.it/?ent=grupporic&id=460>)
- **Multinational Association of Supportive Care in Cancer (MASCC) – Neurological Complications, Cancer Related Cognitive Impairment (CRCI) Subgroup** (Chair: Deborah Allen, Zev Nakamura; <https://mascc.org>)
- **Peripheral Nerve Society (PNS) - Toxic Neuropathy Consortium (TNC) Special Interest Group** (Chair: Guido Cavaletti; <https://pnsociety.com>)
- **Scuola Universitaria Superiore IUSS Pavia - Istituti Clinici Scientifici Maugeri IRCCS, Cognitive Neuroscience Laboratory of Pavia Institute** (Ref. Nicola Canessa)

SCIENTIFIC AFFILIATIONS

- Associazione Italiana per lo Studio del Dolore (AISD)
- American Psychological Association (APA)
- International Parkinson and Movement Disorder Society (MDS)
- Società degli Psicologi di Area Neuropsicologica (SPAN)
- Società Italiana Parkinson e Disordini del Movimento (LIMPE-DISMOV)
- Società Italiana di Riabilitazione Neurologica (SIRN)

EDITORIAL ACTIVITY

- Member of the Editorial Board: Parkinson's Disease (IF: 3.170)
- Review Editor: Frontiers in Psychiatry (IF: 5.435)
- Reviewer: BMJ Open (IF: 3.007), Frontiers in Neurology (IF: 4.086), Immunologic Research (IF: 4.505), PlosOne (IF: 3.752)

INVITED LECTURES/TALKS

- "Motivation and impulsivity in Parkinson's disease: anatomo-functional substrates and therapeutical perspectives" (*invited talk*, XXII Congress of the Italian Society of Neurological Rehabilitation (S.I.R.N.), Riva del Garda, April 16-18, 2023)
- "Non-invasive brain stimulation for the treatment of cognitive and neuropsychiatric non-motor symptoms in Parkinson's disease" (*invited talk*, 9° Congress of the Italian Society of Parkinson's disease and movement disorders/LIMPE-DISMOV, Padova, May 4-6, 2023)
- "How to approach systematic reviews and meta-analyses in pain medicine" (*invited talk*, 46° Congress of the Italian Association for the study of Pain (AISD), Bari, September 28-30, 2023)
- "Non-pharmacological treatments of pain (NIBS and psychotherapy): evidence from the literature" (*invited talk*, XXIII Congress of the Italian Society of Neurological Rehabilitation (S.I.R.N.), Firenze, February 15-17, 2024)
- "Non-invasive brain stimulation" (*invited talk*, AISD/SIN Neuropathic Pain Study Group Joint Session, XXIII Congress of the Italian Association for the study of Pain (AISD), Bergamo, September 19-21, 2024)

PUBLICATIONS

Bibliometrics (Scopus)

<https://www.scopus.com/authid/detail.uri?authorId=57208175437&origin=AuthorEval>

Number of published papers in peer-reviewed journals = 42

Number of received citations = 703

H-index = 12

Peer-reviewed publications

1. **Mantovani E.**, Bressan M.M., Tinazzi M., Tamburin S. Towards multimodal cognition-based treatment for cognitive impairment in Parkinson's disease: drugs, exercise, non-invasive brain stimulation and technologies. *Curr Opin Neurol*, *In press*.
2. Nakamura Z.M., Ali N.T., Crouch A., Dhillon H., Federico A., Gates P., Grech L., Kesler S.R., Ledbetter L., **Mantovani E.**, Mayo S., Ng D.Q., Pembroke L., Pike K.E., Tamburin S., Tan C.J., Toh Y.L., Yang Y., Von Ah D., Allen D.H. Impact of Cognitive Rehabilitation on Cognitive and Functional Outcomes in Adult Cancer Survivors: A Systematic Review. *Semin Oncol Nurs*. 2024 Jul 23;151696. doi: 10.1016/j.soncn.2024.151696.
3. Filippetti M., Tamburin S., Di Censo R., Adamo M., Manera E., Ingrà J., **Mantovani E.**, Facciorusso S., Battaglia M., Baricich A, et al. Role of Diagnostic Nerve Blocks in the Goal-Oriented Treatment of Spasticity with Botulinum Toxin Type A: A Case-Control Study. *Toxins*. 2024; 16(6):258. <https://doi.org/10.3390/toxins16060258>
4. Tamburin S., Paio F., Bovi T., Bulgarelli G., Longhi M., Foroni R., **Mantovani E.**, Polloniato P.M., Tagliamonte M., Zivelonghi E., Zucchella C., Cavedon C., Nicolato A., Petralia B., Sala F., Bonetti B., Tinazzi M., Montemezzi S., Ricciardi G.K. Magnetic resonance-guided focused ultrasound unilateral thalamotomy for medically refractory essential tremor: 3-year follow-up data. *Front Neurol*. 2024 Apr 26;15:1360035. doi: 10.3389/fneur.2024.1360035.
5. Dinoto A., Trentinaglia M., Carta S., **Mantovani E.**, Ferrari S., Tamburin S., Tinazzi M., Mariotto S. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors. *Mov Disord Clin Pract*. 2024 May;11(5):543-549. doi: 10.1002/mdc3.14003.
6. **Mantovani E.**, Martini A., Tamburin S. Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease (Protocol). *Cochrane Database of Systematic Reviews* 2023, Issue 6. Art. No.: CD015046. DOI: 10.1002/14651858.CD015046.
7. Devigili G., Di Stefano G., Donadio V., Frattale I., **Mantovani E.**, Nolano M., Occhipinti G., Provitera V., Quitadamo S., Tamburin S., Toscano A., Tozza S., Truini A., Valeriani M., de Tommaso M. Clinical criteria and diagnostic assessment of fibromyalgia: position statement of the Italian Society of Neurology-Neuropathic Pain Study Group. *Neurol Sci*. 2023 May 24. doi: 10.1007/s10072-023-06836-3. Epub ahead of print. PMID: 37222872.

8. **Mantovani E.**, Zanini A., Cecchini M.P., Tamburin S. The Association Between Neurocognitive Disorders and Gustatory Dysfunction: A Systematic Review and Meta-Analysis. *Neuropsychol Rev.* 2023 Feb 20. doi: 10.1007/s11065-023-09578-3. Epub ahead of print. PMID: 36806051.
9. **Mantovani E.**, Zucchella C., Argyriou A.A., Tamburin S. Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinson's disease: current evidence and future perspectives. *Expert Rev Neurother.* 2023 Jan;23(1):25-43. doi: 10.1080/14737175.2023.2173576.
10. Dinoto A.*, **Mantovani E.***, Ferrari S., Mariotto S., Tamburin S. Cerebellar involvement associated with immune checkpoint inhibitors: a systematic review. *Eur J Neurol.* 2023 Mar;30(3):774-781. doi: 10.1111/ene.15624.
*Shared co-first authorship
11. Tamburin S., Filippetti M., **Mantovani E.**, Smania N., Picelli A. Spasticity following brain and spinal cord injury: assessment and treatment. *Curr Opin Neurol.* 2022 Dec 1;35(6):728-740. doi: 10.1097/WCO.0000000000001114. Epub 2022 Oct 13. PMID: 36226708.
12. **Mantovani E.**, Demrozi F., Hertz D.L., Turetta C., Ferro O., Argyriou A.A., Pravadelli G., Tamburin S. Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy-induced peripheral neurotoxicity: Systematic review and directions for future research. *J Peripher Nerv Syst.* 2022 Oct 12. doi: 10.1111/jns.12518. Epub ahead of print. PMID: 36224713.
13. **Mantovani E.**, Tamburin S. D2/D3 receptor agonism: paving the way for a new therapeutic target for taste disorders in Parkinson's disease and other conditions? *Int J Neuropsychopharmacol.* 2022 Jul 31;pyac042. doi: 10.1093/ijnp/pyac042. Epub ahead of print. PMID: 35908177.
14. Argyriou A.A., **Mantovani E.**, Mitsikostas D.D., Vikelis M., Tamburin S. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. *Expert Rev Neurother.* 2022 Jun 16. doi: 10.1080/14737175.2022.2091435. Epub ahead of print.
15. Tamburin S., Park S.B., Schenone A., **Mantovani E.**, Hamedani M., Alberti P., Yildiz-Kabak V., Kleckner I.R., Kolb N., Mazzucchelli M., McNeish B.L., Argyriou A.A., Cavaletti G., Hoke A.; Toxic Neuropathy Consortium. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. *Crit Rev Oncol Hematol.* 2022 Mar;171:103575. doi: 10.1016/j.critrevonc.2021.103575.
16. Park S.B., Tamburin S., Schenone A., Kleckner I.R., Velasco R., Alberti P., Kanzawa-Lee G., Lustberg M., Dorsey S.G., **Mantovani E.**, Hamedani M., Argyriou A.A., Cavaletti G., Hoke A.; Toxic Neuropathy Consortium. Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. *Expert Rev Neurother.* 2022 Jan;22(1):65-76. doi: 10.1080/14737175.2022.2018300.
17. Zamboni L., Centoni F., Fusina F., **Mantovani E.**, Rubino F., Lugoboni F., Federico A. The Effectiveness of Cognitive Behavioral Therapy Techniques for the Treatment of Substance Use Disorders: A Narrative Review of Evidence. *J Nerv Ment Dis.* 2021 Nov 1;209(11):835-845. doi: 10.1097/NMD.0000000000001381.
18. Deumer U.S., Varesi A., Floris V., Savioli G., **Mantovani E.**, López-Carrasco P., Rosati G.M., Prasad S., Ricevuti G. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview. *J Clin Med.* 2021 Oct 19;10(20):4786. doi: 10.3390/jcm10204786.
19. **Mantovani E.**, Mariotto S., Gabbiani D., Dorelli G., Bozzetti S., Federico A., Zanzoni S., Girelli D., Crisafulli E., Ferrari S., Tamburin S. Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors? *J Neurovirol.* 2021 Aug;27(4):631-637. doi: 10.1007/s13365-021-01002-x. Epub 2021 Aug 2.
20. Cecchini M.P.*, **Mantovani E.***, Federico A., Zanini A., Ottaviani S., Masala C., Tinazzi M., Tamburin S. Olfaction in patients with Parkinson's disease: a new threshold test analysis through turning points trajectories. *J Neural Transm (Vienna).* 2021 Nov;128(11):1641-1653. doi: 10.1007/s00702-021-02387-z. Epub 2021 Jul 30.
*Shared co-first authorship
21. Argyriou A.A., Mitsikostas D.D., **Mantovani E.**, Vikelis M., Tamburin S. Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. *Expert Rev Neurother.* 2021 Jul 22. doi: 10.1080/14737175.2021.1958677. Epub ahead of print.
22. Argyriou A.A., Bruna J., **Mantovani E.**, Tamburin S. Neuromuscular complications of cancer therapy. *Curr Opin Neurol.* 2021 Jun 14. doi: 10.1097/WCO.0000000000000969. Epub ahead of print.

23. Chiamulera C., **Mantovani E.**, Tamburin S. Remote clinical trials: A timely opportunity for a virtual reality approach and its potential application in neurology. *Br J Clin Pharmacol.* 2021 May 26. doi: 10.1111/bcp.14922. Epub ahead of print.
24. Argyriou A.A., Mitsikostas D.D., **Mantovani E.**, Litsardopoulos P., Panagiotopoulos V., Tamburin S. An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. *Expert Rev Neurother.* 2021 Apr;21(4):475-490. doi: 10.1080/14737175.2021.1900734. Epub 2021 Apr 26.
25. Martini A., **Mantovani E.**, Tamburin S. Comment on "The association between pain and impulse control behaviours in Parkinson's disease". *Parkinsonism Relat Disord.* 2021 Feb;83:126-127. doi: 10.1016/j.parkreldis.2021.01.009. Epub 2021 Jan 14.
26. Tamburin S., **Mantovani E.**, De Bernardis E., Zipeto D., Lugoboni F. COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder. *Intern Emerg Med.* 2021 Jan 19:1-3. doi: 10.1007/s11739-021-02633-y. Epub ahead of print.
27. Scuteri D., **Mantovani E.**, Tamburin S., Sandrini G., Corasaniti M.T., Bagetta G., Tonin P. Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2020 Nov 27;11:587050. doi: 10.3389/fphar.2020.587050.
28. Federico A., **Mantovani E.**, Casari R., Bertoldi A., Lugoboni F., Tamburin S. Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug. *J Neural Transm (Vienna).* 2021 Jul;128(7):1109-1119. doi: 10.1007/s00702-020-02285-w. Epub 2020 Dec 17.
29. Tamburin S., **Mantovani E.**, Bertoldi A., Federico A., Casari R., Lugoboni F. High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam. *Front Psychiatry.* 2020 Nov 4;11:601827. doi: 10.3389/fpsy.2020.601827.
30. Zucchella C.*, **Mantovani E.***, De Icco R., Tassorelli C., Sandrini G., Tamburin S. Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review. *Front Neurosci.* 2020 Nov 20;14:547069. doi: 10.3389/fnins.2020.547069.
*Shared co-first authorship
31. Argyriou A.A., Vikelis M., **Mantovani E.**, Litsardopoulos P., Tamburin S. Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. *Expert Rev Neurother.* 2021 Feb;21(2):235-248. doi: 10.1080/14737175.2021.1857240. Epub 2020 Dec 17.
32. **Mantovani E.**, Zucchella C., Bottiroli S., Federico A., Giugno R., Sandrini G., Chiamulera C., Tamburin S. Telemedicine and Virtual Reality for Cognitive Rehabilitation: A Roadmap for the COVID-19 Pandemic. *Front Neurol.* 2020 Sep 15;11:926. doi: 10.3389/fneur.2020.00926.
33. Zucchella C.*, **Mantovani E.***, Federico A., Lugoboni F., Tamburin S. Non-invasive Brain Stimulation for Gambling Disorder: A Systematic Review. *Front Neurosci.* 2020 Aug 18;14:729. doi: 10.3389/fnins.2020.00729.
*Shared co-first authorship
34. Tamburin S., **Mantovani E.**, Lugoboni F. Risk of hospitalization associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments-comment. *Intern Emerg Med.* 2021 Mar;16(2):521-523. doi: 10.1007/s11739-020-02392-2. Epub 2020 Sep 1.
35. Federico A., Lugoboni F., **Mantovani E.**, Martini A., Morbioli L., Casari R., Faccini M., Tamburin S. Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers. *Front Neurosci.* 2020 Jul 21;14:747. doi: 10.3389/fnins.2020.00747.
36. Lugoboni F., Bertoldi A., Casari R., **Mantovani E.**, Morbioli L., Tamburin S. Adult Attention-Deficit/Hyperactivity Disorder and Quality of Life in High-Dose Benzodiazepine and Related Z-Drug Users. *Eur Addict Res.* 2020;26(4-5):274-282. doi: 10.1159/000507852. Epub 2020 Jun 22.
37. **Mantovani E.**, Zucchella C., Schena F., Romanelli M.G., Venturelli M., Tamburin S. Towards a Redefinition of Cognitive Frailty. *J Alzheimers Dis.* 2020;76(3):831-843. doi: 10.3233/JAD-200137.
38. Lugoboni F., Zamboni L., **Mantovani E.**, Cibi M., Gruppo InterSERT di Collaborazione Scientifica (GICS), Tamburin S. Association between adult attention deficit/hyperactivity disorder and intravenous misuse of opioid and benzodiazepine in patients under opioid maintenance treatment: A cross-sectional multicentre study. *Eur Addict Res.* 2020;26(4-5):263-273. doi: 10.1159/000505207. Epub 2020 Jan 29.

39. **Mantovani E.**, Lugoboni F., Federico A., Zipeto D., Tamburin S. Benzodiazepine Use and HIV-Associated Neurocognitive Impairment: Which Comes First? J Acquir Immune Defic Syndr. 2020 Apr 1;83(4):e26-e27. doi: 10.1097/QAI.0000000000002278.
40. Danese A., Federico A., Martini A., **Mantovani E.**, Zucchella C., Tamburin S., Cavallaro T., Marafioti V., Monaco S., Turri G. QTc prolongation in patients with dementia and mild cognitive impairment: cognitive and brain imaging correlations. J Alzheimers Dis. 2019;72(4):1241-1249. doi: 10.3233/JAD-190632.
41. Cecchini M.P., Federico A., Zanini A., **Mantovani E.**, Masala C., Tinazzi M., Tamburin S. Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction. J Neural Transm (Vienna). 2019 May;126(5):585-595. doi: 10.1007/s00702-019-01996-z. Epub 2019 Mar 25.
42. Zucchella C., Sinforiani E., Tamburin S., Federico A., **Mantovani E.**, Bernini S., Casale R., Bartolo M. The multidisciplinary approach to Alzheimer's disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol. 2018 Dec 13;9:1058. doi: 10.3389/fneur.2018.01058.

I authorize the processing of personal data contained in the curriculum vitae based on art. 13 of Legislative Decree 196/2003 and art. 13 GDPR 679/2016. Aware that false declarations entail the application of the penalties provided for by art. 76 of the Presidential Decree 445/2000, I declare that the information reported in the following curriculum vitae is true (Art.45, 46, 48, 76 DPR 28/12/00n.445 and as amended).

Verona, 02/08/2024



